Phuong J, Manon S, Moles R, Mason D, Vleeskens C, Rezae F
Explor Res Clin Soc Pharm. 2024; 15:100488.
PMID: 39318501
PMC: 11419926.
DOI: 10.1016/j.rcsop.2024.100488.
Seki K, Nagasaki M, Yoshino T, Yano M, Kawamoto A, Shimizu O
Diagnostics (Basel). 2024; 14(10).
PMID: 38786307
PMC: 11119882.
DOI: 10.3390/diagnostics14101009.
Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T
Health Technol Assess. 2024; 28(21):1-169.
PMID: 38634483
PMC: 11056815.
DOI: 10.3310/WYPF0472.
Sulaiman N, Fadhul F, Chrcanovic B
Materials (Basel). 2023; 16(18).
PMID: 37763356
PMC: 10532755.
DOI: 10.3390/ma16186078.
Jamil M, Daneshvar A, Nachawati D, El Sharu H, Meysami A
Cureus. 2023; 15(7):e41524.
PMID: 37551226
PMC: 10404464.
DOI: 10.7759/cureus.41524.
Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: A retrospective cohort study.
Seki K, Kaneko T, Kamimoto A, Wada M, Takeuchi Y, Furuchi M
J Dent Sci. 2022; 17(4):1619-1625.
PMID: 36299343
PMC: 9588785.
DOI: 10.1016/j.jds.2022.03.014.
Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies.
Li W, Ning Z, Yang Z, Fan T, Yao M, Zhang W
Arch Osteoporos. 2022; 17(1):84.
PMID: 35715524
DOI: 10.1007/s11657-022-01129-2.
Improving Secondary Bone Protection Prescription in Patients Admitted With a Femoral Neck Fracture.
Hamid M, Chikhlia A, Gogna A
Cureus. 2021; 13(10):e18883.
PMID: 34820213
PMC: 8600251.
DOI: 10.7759/cureus.18883.
Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials.
Hirota M, Takahashi T, Saito Y, Kawabata R, Nakatsuka R, Imamura H
Ann Gastroenterol Surg. 2021; 5(6):754-766.
PMID: 34755007
PMC: 8560613.
DOI: 10.1002/ags3.12474.
Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.
Nakamura Y, Shimizu T, Asano T, Shimodan S, Ishizu H, Takahashi D
J Bone Miner Metab. 2021; 39(5):824-832.
PMID: 33821302
PMC: 8021003.
DOI: 10.1007/s00774-021-01221-6.
A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis.
Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M
Osteoporos Sarcopenia. 2021; 6(4):191-198.
PMID: 33426308
PMC: 7783076.
DOI: 10.1016/j.afos.2020.11.002.
A Mixed Methods Study Exploring Older Womens' Attitudes Toward Osteoporosis Medications: Adapting a Health Communication Framework.
Fuzzell L, Fraenkel L, Stark S, Seehra S, Nelson C, Keleman A
Womens Health Rep (New Rochelle). 2020; 1(1):102-113.
PMID: 32617530
PMC: 7325487.
DOI: 10.1089/whr.2019.0014.
Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study.
Howe J, Hill R, Stroncek J, Shaul J, Favell D, Cheng R
Osteoporos Int. 2019; 31(5):921-929.
PMID: 31802158
PMC: 7170985.
DOI: 10.1007/s00198-019-05230-0.
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
Soen S, Kishimoto H, Hagino H, Sone T, Ohishi H, Fujimoto T
J Bone Miner Metab. 2019; 38(1):86-98.
PMID: 31420748
DOI: 10.1007/s00774-019-01031-x.
Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and....
Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E
Osteoporos Int. 2019; 30(11):2155-2165.
PMID: 31388696
PMC: 6811382.
DOI: 10.1007/s00198-019-05104-5.
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag K, Pannacciulli N, Geusens P, Adachi J, Messina O, Morales-Torres J
Arthritis Rheumatol. 2019; 71(7):1174-1184.
PMID: 30816640
PMC: 6619388.
DOI: 10.1002/art.40874.
Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
Naylor K, McCloskey E, Jacques R, Peel N, Paggiosi M, Gossiel F
Osteoporos Int. 2019; 30(4):917-922.
PMID: 30613868
DOI: 10.1007/s00198-018-04823-5.
MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.
Patel V, Mansi J, Ghosh S, Kwok J, Burke M, Reilly D
Br Dent J. 2017; 224(2):74-79.
PMID: 29242516
DOI: 10.1038/sj.bdj.2017.1039.
Prescribing Physical Activity for the Prevention and Treatment of Osteoporosis in Older Adults.
McMillan L, Zengin A, Ebeling P, Scott D
Healthcare (Basel). 2017; 5(4).
PMID: 29113119
PMC: 5746719.
DOI: 10.3390/healthcare5040085.
Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
Park J, Park E, Koo D, Lee S, Lee S, Kim G
BMC Musculoskelet Disord. 2017; 18(1):152.
PMID: 28399834
PMC: 5387221.
DOI: 10.1186/s12891-017-1514-4.